Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Imjudo |
|---|---|
| Manufacturer | AstraZeneca GmbH |
| Prescription required | Yes |
Imjudo injection 300mg/15ml(tremelimuma-actl)
tremelimuma-actl
Description
Imjudo injection 300mg/15ml(tremelimuma-actl) is a medicine catalog record in the MediPriceHub database. Active ingredient: tremelimuma-actl. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: AstraZeneca GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Hepatocellular Carcinoma. Pack information: 300 / 15 (20 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.How to Use
Use tremelimuma-actl under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: tremelimuma-actl. Pack size: 300 / 15 (20 / ). Pack unit: bottle. Manufacturer: AstraZeneca GmbH. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Hepatocellular Carcinoma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.